Characteristics of deslanoside-induced modulation on jejunal contractility

Figure 4 Effects of deslanoside on the contractility of jejunal smooth muscle fragment in Ca²⁺-free conditions. A: Representative traces of deslanoside (20 μmol/L) on the contractility of jejunal smooth muscle fragment (JSMF) pre-treated with verapamil (0.1 μmol/L) in normal contractile state (NCS), representative low contractile state (RLCS) and representative high contractile state (RHCS); B: Representative traces of deslanoside (5-80 μmol/L) on the contractility of JSMF pre-treated with Ca²⁺-free Krebs buffer; C, D: Statistical analysis obtained from 6 independent assays in identical assay conditions as (A) and as (B). The mean contractile amplitude of JSMF without drug treatment in NCS is set to a relative value of 100%, other data are expressed as mean ± SE (% NCS, n = 6); ^bP < 0.01 vs the control group.